Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Bristol-Myers Squibb
7 Hills Pharma, LLC
Memorial Sloan Kettering Cancer Center
National Institutes of Health Clinical Center (CC)
West China Hospital
Pfizer
National Institutes of Health Clinical Center (CC)
State University of New York at Buffalo
Aulos Bioscience, Inc.
Bristol-Myers Squibb
3D Medicines
BeOne Medicines
Merck Sharp & Dohme LLC